Cargando...
A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma
BACKGROUND: The purpose of the current study was to evaluate the efficacy and safety of a dose increased weekly Bortezomib (Bor) based combination therapy in multiple myeloma (MM) patients. RESULTS: The overall response rate (ORR) in the modified Bor group was 76.6%, composed of 40% complete respons...
Gardado en:
| Publicado en: | Oncotarget |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Impact Journals LLC
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5342543/ https://ncbi.nlm.nih.gov/pubmed/27659525 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12162 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|